66 results
424B4
PPCB
Propanc Biopharma, Inc.
16 Oct 23
Prospectus supplement with pricing info
8:21pm
those risks. While our board of directors has ultimate oversight responsibility for the risk management process given that no board committees have … that might result from the outcome of this uncertainty.
Basis for Opinion
These consolidated financial statements are the responsibility
8-K
EX-10.1
v5l5s z1y
15 May 23
Entry into a Material Definitive Agreement
4:06pm
424B3
6sgdo2z87wma
4 Apr 23
Prospectus supplement
11:22am
8-K
EX-10.1
93te4xqxtma
1 Nov 22
Departure of Directors or Certain Officers
5:11pm
424B3
bb0bbs
22 Feb 22
Prospectus supplement
11:53am
POS AM
4dnl 3g84ka
10 Jan 22
Prospectus update (post-effective amendment)
4:46pm
8-K
EX-10.5
xr3689belc
18 Aug 21
Entry into a Material Definitive Agreement
6:06am
8-K
EX-10.2
i3r35bvi 7ci09fqlmfl
30 Dec 20
Departure of Directors or Certain Officers
2:35pm
8-K
EX-10.1
kcx3s6ghzb3 w1p7l0
30 Dec 20
Departure of Directors or Certain Officers
2:35pm
CORRESP
e15tik52684 uh7ynes
10 Nov 20
Correspondence with SEC
12:00am